Compared to that in the normal group, the GCC2 protein level increased progressively in the patients as the pathological stages of lung cancer progressed (Supplementary Figure S2), indicating that GCC2+ exosomes could be a reliable biomarker to detect NSCLC. This evidence concerns the gene GCC2 and non-small cell lung carcinoma.